What does CUSIP 87650L103 represent in this 13F holders report?

CUSIP 87650L103 is the security identifier for TARS - Tarsus Pharmaceuticals, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held TARS - Tarsus Pharmaceuticals, Inc. - Common Stock in Q4 2020?

39 institutional investors reported TARS - Tarsus Pharmaceuticals, Inc. - Common Stock for Q4 2020. Use the holders table for investor-level position and value details.

Tarsus Pharmaceuticals, Inc. - Common Stock (TARS)

CUSIP: 87650L103

Q4 2020 13F Holders as of 31 Dec 2020

Type / Class: Equity / Common Stock
Shares outstanding: 42,450,857
Total 13F shares: 12,759,585
Share change: +12,759,585
Total reported value: $523,637,183
Price per share: $41.33
Number of holders: 39
Value change: +$523,637,191
Number of buys: 39

Quarterly Holders Quick Answers

What is CUSIP 87650L103?
CUSIP 87650L103 identifies TARS - Tarsus Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2021

Recent filing periods for CUSIP 87650L103:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of TARS - Tarsus Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) as of Q4 2020

As of 31 Dec 2020, Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) was held by 39 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 12,759,585 shares. The largest 10 holders included Vivo Capital, LLC, RTW INVESTMENTS, LP, FRAZIER MANAGEMENT LLC, Cormorant Asset Management, LP, PERCEPTIVE ADVISORS LLC, TimesSquare Capital Management, LLC, BlackRock Inc., VANGUARD GROUP INC, SANDS CAPITAL MANAGEMENT, LLC, and Ensign Peak Advisors, Inc. This page lists 39 institutional shareholders reporting positions in this security for the Q4 2020 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2020 vs Q4 2025 Across Filers

Q4 2025 holders

245

Q4 2020 holders

Holder diff

-206

Investor	Q4 2025 Shares	Q4 2020 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q4 2020 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.